Llwytho...
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients
Background: HER2+ metastatic breast cancer (MBC) is a poor prognosis disease, unusually curable. To date, no predictive factors have been clearly correlated with long-term response to anti-HER2 agents. Methods: 54 HER2+ MBC patients treated with HER2 targeted therapy as first line treatment were ana...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Cancer Biol Ther |
|---|---|
| Prif Awduron: | , , , , , , , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Taylor & Francis
2018
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6300343/ https://ncbi.nlm.nih.gov/pubmed/30067438 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2018.1480287 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|